Caris Life Sciences (NASDAQ:CAI) is a company focused on molecular science and technology. It provides services like molecular profiling, which helps doctors understand diseases at a genetic level. A key product is its Caris Assure® test, a blood-based test that analyzes biomarkers to guide cancer treatment. Caris Life Sciences (NASDAQ:CAI) received a "Perform" rating from New Street, despite its stock experiencing significant downward pressure and hitting a new 52-week low. The company demonstrated robust ...